Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NATR's Cash to Debt is ranked higher than
98% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. NATR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NATR' s Cash to Debt Range Over the Past 10 Years
Min: 2.51  Med: 21.55 Max: No Debt
Current: No Debt
Equity to Asset 0.64
NATR's Equity to Asset is ranked higher than
50% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NATR: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
NATR' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.63 Max: 0.73
Current: 0.64
0.31
0.73
Interest Coverage No Debt
NATR's Interest Coverage is ranked higher than
97% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. NATR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NATR' s Interest Coverage Range Over the Past 10 Years
Min: 13.14  Med: 95.49 Max: 9999.99
Current: No Debt
13.14
9999.99
F-Score: 6
Z-Score: 3.47
M-Score: -2.47
WACC vs ROIC
6.55%
10.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.30
NATR's Operating margin (%) is ranked lower than
64% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. NATR: 3.30 )
Ranked among companies with meaningful Operating margin (%) only.
NATR' s Operating margin (%) Range Over the Past 10 Years
Min: 0.83  Med: 3.26 Max: 9.26
Current: 3.3
0.83
9.26
Net-margin (%) 3.43
NATR's Net-margin (%) is ranked lower than
62% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. NATR: 3.43 )
Ranked among companies with meaningful Net-margin (%) only.
NATR' s Net-margin (%) Range Over the Past 10 Years
Min: -2.25  Med: 1.39 Max: 6.91
Current: 3.43
-2.25
6.91
ROE (%) 8.41
NATR's ROE (%) is ranked higher than
56% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. NATR: 8.41 )
Ranked among companies with meaningful ROE (%) only.
NATR' s ROE (%) Range Over the Past 10 Years
Min: -12.81  Med: 6.46 Max: 25
Current: 8.41
-12.81
25
ROA (%) 5.52
NATR's ROA (%) is ranked higher than
60% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. NATR: 5.52 )
Ranked among companies with meaningful ROA (%) only.
NATR' s ROA (%) Range Over the Past 10 Years
Min: -5.25  Med: 3.06 Max: 13.73
Current: 5.52
-5.25
13.73
ROC (Joel Greenblatt) (%) 14.22
NATR's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. NATR: 14.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NATR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 15.41  Med: 46.28 Max: 120.79
Current: 14.22
15.41
120.79
Revenue Growth (3Y)(%) -3.90
NATR's Revenue Growth (3Y)(%) is ranked lower than
76% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NATR: -3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NATR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 3.65 Max: 8.7
Current: -3.9
-3.9
8.7
EBITDA Growth (3Y)(%) -7.30
NATR's EBITDA Growth (3Y)(%) is ranked lower than
76% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NATR: -7.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NATR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.5  Med: 0.55 Max: 29.8
Current: -7.3
-27.5
29.8
» NATR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NATR Guru Trades in Q2 2015

Jim Simons 245,500 sh (+17.07%)
Chuck Royce Sold Out
» More
Q3 2015

NATR Guru Trades in Q3 2015

Jim Simons 269,700 sh (+9.86%)
» More
Q4 2015

NATR Guru Trades in Q4 2015

Jim Simons 287,100 sh (+6.45%)
» More
Q1 2016

NATR Guru Trades in Q1 2016

Jim Simons 340,100 sh (+18.46%)
» More
» Details

Insider Trades

Latest Guru Trades with NATR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:XKRX:214390, OCSE:VELO, NAS:KPTI, LSE:APH, XKRX:002250, TSE:4594 » details
Natures Sunshine Products Inc is a natural health and wellness company. The Company, together with its subsidiaries is engaged in the manufacturing and direct selling of nutritional and personal care products.

Natures Sunshine Products Inc, was founded in 1972 and incorporated in Utah in 1976. The Company together with its subsidiaries is a natural health and wellness company engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent Managers and Distributors who use the products themselves or resell them to other distributors or customers. The Company has two reportable business segments that operate under the Nature's Sunshine Products brand and are divided based on their geographic operations in the United States and in countries outside the United States. The Company's third reportable business segment operates under the Synergy brand, which offers marketing plans, Distributor compensation plans and product formulations that are sufficiently different from those of NSP United States and NSP International to warrant accounting for these operations as a separate business segment. The Company has line of over 700 products includes several different product classifications, such as immunity, cardiovascular, digestive, personal care, weight management as well as other general health products. It purchase herbs and other raw materials in bulk and, after quality control testing, it formulate, encapsulate, tablet or concentrate them, and package them for shipment. Its products are manufactured at its facility in Spanish Fork, Utah. Contract manufacturers produce some of its vitamins, mineral and other nutritional supplements, personal care products and certain other miscellaneous products in accordance with its specifications and standards. The Company's independent Distributors market its products to customers through direct-selling techniques, as well as sponsoring other Distributors. Its products sold in the United States are shipped directly from its manufacturing and warehouse facilities located in Spanish Fork, Utah, as well as from its regional warehouses located in Georgia, Ohio and Texas. Its international operations maintain warehouse facilities with inventory to supply their customers. The Company's product lines by category includes; General health is a combination of assorted health products related to blood sugar support, bone health, cellular health, cognitive function, essential oils, joint health, mood, sexual health, sleep, sports and energy, and vision; Immunity line has been designed to offer products that support and strengthen the human immune system; Cardiovascular line has been designed to offer products that combine a variety of superior heart health ingredients to give the cardiovascular system optimum support; Disgestive line has been designed to offer products that regulate intestinal and digestive functions in support of the human digestive system; Personal care products for external use, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste and skin cleanser; and Weight manageme

Ratios

vs
industry
vs
history
P/E(ttm) 15.85
NATR's P/E(ttm) is ranked higher than
76% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. NATR: 15.85 )
Ranked among companies with meaningful P/E(ttm) only.
NATR' s P/E(ttm) Range Over the Past 10 Years
Min: 7.88  Med: 17.53 Max: 159.88
Current: 15.85
7.88
159.88
PE(NRI) 18.38
NATR's PE(NRI) is ranked higher than
69% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. NATR: 18.38 )
Ranked among companies with meaningful PE(NRI) only.
NATR' s PE(NRI) Range Over the Past 10 Years
Min: 7.89  Med: 15.13 Max: 87
Current: 18.38
7.89
87
Price/Owner Earnings (ttm) 57.07
NATR's Price/Owner Earnings (ttm) is ranked lower than
69% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. NATR: 57.07 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NATR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.13  Med: 31.35 Max: 4175
Current: 57.07
7.13
4175
P/B 1.30
NATR's P/B is ranked higher than
79% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. NATR: 1.30 )
Ranked among companies with meaningful P/B only.
NATR' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 2.13 Max: 3.88
Current: 1.3
1.04
3.88
P/S 0.54
NATR's P/S is ranked higher than
91% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. NATR: 0.54 )
Ranked among companies with meaningful P/S only.
NATR' s P/S Range Over the Past 10 Years
Min: 0.21  Med: 0.62 Max: 1.95
Current: 0.54
0.21
1.95
POCF 12.63
NATR's POCF is ranked higher than
68% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. NATR: 12.63 )
Ranked among companies with meaningful POCF only.
NATR' s POCF Range Over the Past 10 Years
Min: 6.32  Med: 13.31 Max: 162.25
Current: 12.63
6.32
162.25
EV-to-EBIT 12.39
NATR's EV-to-EBIT is ranked higher than
73% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. NATR: 12.39 )
Ranked among companies with meaningful EV-to-EBIT only.
NATR' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.1  Med: 9.40 Max: 136.6
Current: 12.39
3.1
136.6
EV-to-EBITDA 8.47
NATR's EV-to-EBITDA is ranked higher than
80% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. NATR: 8.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
NATR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.6  Med: 7.10 Max: 31.5
Current: 8.47
2.6
31.5
PEG 2.79
NATR's PEG is ranked lower than
62% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. NATR: 2.79 )
Ranked among companies with meaningful PEG only.
NATR' s PEG Range Over the Past 10 Years
Min: 0.21  Med: 0.46 Max: 8.48
Current: 2.79
0.21
8.48
Shiller P/E 20.60
NATR's Shiller P/E is ranked higher than
81% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. NATR: 20.60 )
Ranked among companies with meaningful Shiller P/E only.
NATR' s Shiller P/E Range Over the Past 10 Years
Min: 7.73  Med: 21.25 Max: 47.62
Current: 20.6
7.73
47.62
Current Ratio 1.77
NATR's Current Ratio is ranked lower than
64% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. NATR: 1.77 )
Ranked among companies with meaningful Current Ratio only.
NATR' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.08 Max: 2.48
Current: 1.77
1.32
2.48
Quick Ratio 1.10
NATR's Quick Ratio is ranked lower than
73% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. NATR: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
NATR' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.30 Max: 1.79
Current: 1.1
0.83
1.79
Days Inventory 172.42
NATR's Days Inventory is ranked lower than
75% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. NATR: 172.42 )
Ranked among companies with meaningful Days Inventory only.
NATR' s Days Inventory Range Over the Past 10 Years
Min: 163.98  Med: 191.77 Max: 212.68
Current: 172.42
163.98
212.68
Days Sales Outstanding 9.20
NATR's Days Sales Outstanding is ranked higher than
94% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. NATR: 9.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
NATR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.2  Med: 8.73 Max: 10.32
Current: 9.2
6.2
10.32
Days Payable 36.97
NATR's Days Payable is ranked lower than
80% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. NATR: 36.97 )
Ranked among companies with meaningful Days Payable only.
NATR' s Days Payable Range Over the Past 10 Years
Min: 20.87  Med: 28.56 Max: 44.57
Current: 36.97
20.87
44.57

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.35
NATR's Dividend Yield is ranked higher than
90% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. NATR: 4.35 )
Ranked among companies with meaningful Dividend Yield only.
NATR' s Dividend Yield Range Over the Past 10 Years
Min: 0.3  Med: 2.35 Max: 5.34
Current: 4.35
0.3
5.34
Dividend Payout 0.75
NATR's Dividend Payout is ranked lower than
84% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. NATR: 0.75 )
Ranked among companies with meaningful Dividend Payout only.
NATR' s Dividend Payout Range Over the Past 10 Years
Min: 0.1  Med: 0.16 Max: 1.67
Current: 0.75
0.1
1.67
Forward Dividend Yield 4.38
NATR's Forward Dividend Yield is ranked higher than
88% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.62 vs. NATR: 4.38 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.35
NATR's Yield on cost (5-Year) is ranked higher than
77% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.95 vs. NATR: 4.35 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NATR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.3  Med: 2.35 Max: 5.34
Current: 4.35
0.3
5.34
3-Year Average Share Buyback Ratio -6.20
NATR's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 425 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. NATR: -6.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NATR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6.2  Med: -0.10 Max: 4.8
Current: -6.2
-6.2
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 5.08
NATR's Price/Net Current Asset Value is ranked higher than
64% of the 452 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. NATR: 5.08 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NATR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.84  Med: 5.51 Max: 118.75
Current: 5.08
2.84
118.75
Price/Tangible Book 1.29
NATR's Price/Tangible Book is ranked higher than
82% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NATR: 1.29 )
Ranked among companies with meaningful Price/Tangible Book only.
NATR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.34  Med: 2.27 Max: 10.63
Current: 1.29
1.34
10.63
Price/Projected FCF 1.13
NATR's Price/Projected FCF is ranked higher than
82% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. NATR: 1.13 )
Ranked among companies with meaningful Price/Projected FCF only.
NATR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.24 Max: 2.37
Current: 1.13
0.42
2.37
Price/Median PS Value 0.88
NATR's Price/Median PS Value is ranked higher than
72% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. NATR: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
NATR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 1.05 Max: 3.66
Current: 0.88
0.34
3.66
Price/Graham Number 1.02
NATR's Price/Graham Number is ranked higher than
81% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. NATR: 1.02 )
Ranked among companies with meaningful Price/Graham Number only.
NATR' s Price/Graham Number Range Over the Past 10 Years
Min: 0.66  Med: 1.29 Max: 4.2
Current: 1.02
0.66
4.2
Earnings Yield (Greenblatt) (%) 8.09
NATR's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. NATR: 8.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NATR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 10.60 Max: 32.3
Current: 8.09
0.7
32.3
Forward Rate of Return (Yacktman) (%) -10.32
NATR's Forward Rate of Return (Yacktman) (%) is ranked lower than
79% of the 323 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.36 vs. NATR: -10.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NATR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -15.8  Med: 4.10 Max: 40
Current: -10.32
-15.8
40

More Statistics

Revenue (TTM) (Mil) $323.2
EPS (TTM) $ 0.58
Beta0.64
Short Percentage of Float2.65%
52-Week Range $7.15 - 14.11
Shares Outstanding (Mil)18.72
» More Articles for NATR

Headlines

Articles On GuruFocus.com
Nature's Sunshine CEO Resigns and Director Buys 365,000 Shares Mar 12 2013 
Is Nature’s Sunshine Breaking Through the Clouds? Mar 28 2012 

More From Other Websites
NATURES SUNSHINE PRODUCTS INC Financials May 19 2016
Nature’s Sunshine Products to Present at the 17th Annual B. Riley & Co. Investor Conference May 18 2016
Nature’s Sunshine Products, Inc. :NATR-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 11 2016
Nature's Sunshine posts 1Q profit May 10 2016
Nature's Sunshine posts 1Q profit May 10 2016
Nature’s Sunshine Products Reports First Quarter 2016 Financial Results May 10 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 10-Q, Quarterly Report May 10 2016
Nature's Sunshine Products Reports First Quarter 2016 Financial Results May 10 2016
Q1 2016 Natures Sunshine Products Inc Earnings Release - 4:00 pm ET May 10 2016
Prescott Group is Betting Big on These Micro-Cap Stocks for Q2 May 02 2016
Nature’s Sunshine to Announce First Quarter 2016 Financial Results and to Host Conference Call on... Apr 26 2016
Nature’s Sunshine Products to Announce First Quarter 2016 Financial Results and to Host Conference... Apr 26 2016
Nature’s Sunshine Honored as a Top Global Company by Direct Selling News Apr 25 2016
Nature’s Sunshine Honored as a Top Global Company by Direct Selling News Apr 25 2016
Nature’s Sunshine Launches Patent-Pending Program to Reverse Cardiometabolic Dysfunction Apr 18 2016
Nature’s Sunshine Launches Patent-Pending Program to Reverse Cardiometabolic Dysfunction Apr 18 2016
Nature’s Sunshine Products to Present at the Sidoti Spring 2016 Emerging Growth Mar 23 2016
Nature’s Sunshine Products to Present at the Sidoti Spring 2016 Emerging Growth Convention Mar 23 2016
NATURES SUNSHINE PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)